CoLucid Pharmaceuticals (CLCD) to Offer Common Shares

September 8, 2016 4:02 PM EDT
Get Alerts CLCD Hot Sheet
Trade CLCD Now!
Join SI Premium – FREE

Get access to the best calls on Wall Street with's Ratings Insider Elite. Get your Free Trial here.

CoLucid Pharmaceuticals, Inc. (Nasdaq: CLCD), a biopharmaceutical company that is developing lasmiditan oral tablets for the acute treatment of migraine in adults, today announced that it intends to offer and sell shares of its common stock. CoLucid also intends to grant the underwriters a 30-day option to purchase up to an additional 15% of the shares of common stock sold in the public offering on the same terms and conditions. All of the shares of the common stock to be sold in the proposed offering will be sold by CoLucid.

Piper Jaffray & Co. and Barclays Capital Inc. are acting as joint book-running managers for the proposed offering.

Serious News for Serious Traders! Try Premium Free!

You May Also Be Interested In

Related Categories

Corporate News, Equity Offerings

Related Entities

Piper Jaffray, Barclays

Add Your Comment